IMVT - Immunovant, Inc.

27.08
0.370   1.366%

Share volume: 1,244,127
Last Updated: 03-04-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.44%

PREVIOUS CLOSE
CHG
CHG%
$26.71
0.37
0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
21%
Profitability 25%
Dept financing 4%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-2.41%
1 Month
12.55%
3 Months
18.56%
6 Months
57.99%
1 Year
39.44%
2 Year
-20.28%
Key data
Stock price
$27.08
P/E Ratio 
0.00
DAY RANGE
$26.60 - $27.53
EPS 
-$2.68
52 WEEK RANGE
$12.72 - $29.25
52 WEEK CHANGE
$38.73
MARKET CAP 
4.456 B
YIELD 
N/A
SHARES OUTSTANDING 
203.532 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-05-2025
BETA 
0.40
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,119,142
AVERAGE 30 VOLUME 
$1,342,271
Company detail
CEO: Peter Salzmann
Region: US
Website: immunovant.com
Employees: 120
IPO year: 2019
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. IMVT-1401 is in Phase IIa clinical trials for the. treatment of myasthenia gravis and thyroid eye disease. The company is headquartered in New York, New York.

Recent news